Purpose: Micro ribonucleic acids (miRNAs) regulate protein translation throughout the human body, influencing diverse processes such as brain development and metabolism. Brain to saliva transfer of miRNAs may occur through the cranial nerves, glymphatic drainage or perfusion of the salivary glands. They are altered in psychiatric conditions, such as depression, but have not been studied in anorexia nervosa (AN), a disorder with both psychiatric and metabolic features. The purpose of this study was to identify salivary miRNAs "altered" in AN that may offer diagnostic and therapeutic targets.
Purpose: Alterations in the gastrointestinal (GI) microbiome and gut-brain axis have been demonstrated in a range of neuropsychiatric disorders, likely through gene-environment interactions. Anorexia nervosa (AN) is a life-threatening mental illness with strong genetic underpinnings, and is characterized by dysregulated psychologic, metabolic and weight-regulation processes. The GI microbiome is implicated in many of these processes, affecting weight loss/gain, energy extraction from the diet, and communication with the brain via the gut-brain axis. The oropharynx represents the sole entry-point of the GI tract, lying in close proximity to the brain and cranial nerves. Evidence has shown that the microbial community residing in the oral cavity is a close representation of that in the upper GI tract, suggesting a role for the salivary microbiome as a diagnostic and prognostic tool for diseases affecting the GI tract. The oropharynx may represent a site of AN pathology, e.g. decreased taste sensation. Preliminary research suggests intestinal dysbiosis in AN, but the salivary microbiome has not been investigated.
Methods:
We characterized the salivary microbiome of females (age 11-21 years) with AN restrictive-type at the outset of treatment, in comparison to healthy controls (HC) and patients with anxiety (AX), a common comorbid diagnosis. Morning pre-and post-prandial salivary samples, and AN post-treatment samples, were collected (n=70). RNA sequencing was used to compare differences in taxa activity (at multiple taxonomic ranks), as well as alpha diversity (within sample) and beta diversity (between sample) among AN, AX, and HC groups. For global analysis, microbiome activity differences between groups were evaluated via permutational analysis of variance (PERMANOVA). The Wilcoxon rank sum test was used to identify differential activity of each individual taxon between groups and across pre/post-treatment AN samples.
Results:
There was a significant difference in the global microbiome activity between AN and HC groups (p=0.004) as reflected by both alpha-diversity and beta-diversity comparisons, indicating salivary dysbiosis in AN. Six genera showed significantly different abundances between AN and HC samples, four of which were more abundant in AN and two of which were less abundant in AN. Rhodobacter, a genus more abundant in AN, includes species which possess an extensive range of metabolic capabilities. Leptospira, also more abundant in AN, is a spirochete bacteria that causes generalized symptoms such as vomiting, jaundice, abdominal pain, and diarrhea. Individual taxa comparisons between AN and AX/HC identified 13 taxa which uniquely characterized AN microbial samples, including enrichment in Proteobacteria and depletion in Firmicutes. Pre-and posttreatment comparison demonstrated a shift in activity of these 13 taxa towards a healthier state after treatment.
Conclusions:
This study presents evidence of upper GI microbiome dysbiosis in AN, consistent with previous gut microbiome findings. Several of the genera differentially expressed in AN are implicated in functional pathways that are characteristically dysregulated in the disease state of AN. Additionally, the salivary microbiome appears to improve to a healthier state following treatment. Future directions include uncovering the differential effects of nutrition/weight restoration and psychological improvement. 
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IMPACT OF ADRENAL AND GONADAL HORMONE SUPPLEMENTATION ON BONE GEOMETRY IN TEENS WITH
Robert Wood Johnson Medical School
Purpose: Adolescents with anorexia nervosa (AN) may have reduced secretion of dehydroepiandrosterone (DHEA) and estrogen that contributes to skeletal deficits. We sought to determine whether DHEA + estrogen replacement therapy (ERT) prevented bone loss in young adolescent girls with AN.
Methods:
We recruited females with AN (n=70), ages 11-18 years, from two hospital-based adolescent clinics into a 12-month, double-blind, placebo-controlled trial. Participants were randomized to receive either oral micronized DHEA 50 mg + 20 mcg ethinyl estradiol/0.1 mg levonorgestrel daily (n=35) or placebo (n=35). Main outcomes included measurements of bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA; total body, hip, lumbar spine) and peripheral quantitative computed tomography (pQCT; tibia) at baseline, 6 months, and 12 months. MRI T1-weighted images of the left knee + T1 relaxometry were obtained to determine physeal status. Biomarkers of bone turnover were measured. We analyzed each outcome using repeatedmeasures analysis of variance. Models were adjusted for age, baseline height and weight, menarchal status, duration of amenorrhea, and physeal status (open or at least partially closed).
Results: Sixty two subjects completed the trial. Physeal closure status was the strongest predictor of changes in aBMD. In participants with open physes at baseline, total body BMD-Z score decreased over 12 months in participants receiving DHEA+ERT (-0.9 ± 0.5, p=0.02) and remained unchanged in placebo subjects (pdifference=0.02). Similar declines in BMD Z-score over time DHEA+ERT were seen at the spine (-1.5 ± 0.5, p=0.01) and hip (-0.5 ± 0.6, p=0.03) in subjects receiving; no changes were observed for placebo subjects. In contrast, in participants with ¬closed physes, no changes in BMD Z-scores were detected at any site with DHEA+ERT or placebo (pdifference >0.05 for all). Treatment did not affect any pQCT measures over the 12-month trial, regardless of physeal closure status. Bone formation markers responded most strongly in the DHEA+ERT group and those with open physes.
Conclusions:
In young adolescents with AN and open physes, replacement of adrenal and gonadal hormones led to a decline in markers of bone health over 12 months of treatment. No benefit of treatment was seen in skeletal outcomes obtained at either the axial or appendicular skeleton. Physeal closure status was an important effect modifier of the impact of hormonal therapy on these bone outcomes. It appears that subjects with open physes at baseline showed decreases in aBMD and BMD Z-scores in response to this therapy. The data suggest that the previously demonstrated potential skeletal benefits derived from this therapy apply only to older adolescents and young women who have completed their growth and have closed epiphyses. Therefore, other therapeutic strategies would be recommended in young patients affected with this disease, in addition to standard multidisciplinary care including medical, nutritional, and psychological support. 
Sources of
